[{"address1": "910 Clopper Road", "address2": "Suite 201S", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 654 1450", "website": "https://altimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Vipin K. Garg Ph.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 986142, "exercisedValue": 0, "unexercisedValue": 4219457}, {"maxAge": 1, "name": "Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS", "age": 70, "title": "Chief Medical Officer", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 681809, "exercisedValue": 0, "unexercisedValue": 1413049}, {"maxAge": 1, "name": "Mr. Raymond M. Jordt M.B.A.", "age": 50, "title": "Chief Business Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 578850, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard I. Eisenstadt M.B.A.", "age": 65, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 619694, "exercisedValue": 0, "unexercisedValue": 273375}, {"maxAge": 1, "name": "Mr. Bertrand  Georges Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. M. Scot Roberts Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 599255, "exercisedValue": 0, "unexercisedValue": 565469}, {"maxAge": 1, "name": "Mr. Tony  Blandin B.S.", "title": "Vice President of Quality & Compliance Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Shutterly M.S.", "title": "Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 3, "compensationRisk": 8, "shareHolderRightsRisk": 4, "overallRisk": 5, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome", "maxAge": 86400, "priceHint": 2, "previousClose": 8.61, "open": 8.6, "dayLow": 8.12, "dayHigh": 8.71, "regularMarketPreviousClose": 8.61, "regularMarketOpen": 8.6, "regularMarketDayLow": 8.12, "regularMarketDayHigh": 8.71, "exDividendDate": 1484870400, "beta": 0.059, "forwardPE": -4.7457623, "volume": 2824467, "regularMarketVolume": 2824467, "averageVolume": 5352426, "averageVolume10days": 4537160, "averageDailyVolume10Day": 4537160, "bid": 8.38, "ask": 8.42, "bidSize": 1100, "askSize": 1400, "marketCap": 595520448, "fiftyTwoWeekLow": 2.09, "fiftyTwoWeekHigh": 14.84, "priceToSalesTrailing12Months": 1397.9353, "fiftyDayAverage": 9.8612, "twoHundredDayAverage": 5.748775, "currency": "USD", "enterpriseValue": 398376416, "floatShares": 70334504, "sharesOutstanding": 70895296, "sharesShort": 17730966, "sharesShortPriorMonth": 10813162, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.25010002, "heldPercentInsiders": 0.0077600004, "heldPercentInstitutions": 0.51448, "shortRatio": 3.42, "shortPercentOfFloat": 0.2521, "impliedSharesOutstanding": 70895296, "bookValue": 2.746, "priceToBook": 3.0589948, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -88447000, "trailingEps": -1.66, "forwardEps": -1.77, "lastSplitFactor": "1:30", "lastSplitDate": 1536883200, "enterpriseToRevenue": 935.156, "enterpriseToEbitda": -4.798, "52WeekChange": 1.0437956, "SandP52WeekChange": 0.27320957, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ALT", "underlyingSymbol": "ALT", "shortName": "Altimmune, Inc.", "longName": "Altimmune, Inc.", "firstTradeDateEpochUtc": 1495805400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "dfbfc9cc-7a23-3560-b04c-b1a5faf1ec3e", "messageBoardId": "finmb_4866807", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.4, "targetHighPrice": 35.0, "targetLowPrice": 12.0, "targetMeanPrice": 21.25, "targetMedianPrice": 22.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 197815008, "totalCashPerShare": 2.79, "ebitda": -83033000, "totalDebt": 671000, "quickRatio": 16.69, "currentRatio": 17.263, "totalRevenue": 426000, "debtToEquity": 0.346, "revenuePerShare": 0.008, "returnOnAssets": -0.24999, "returnOnEquity": -0.46626, "freeCashflow": -49978624, "operatingCashflow": -75810000, "operatingMargins": -573.0811, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-10"}]